Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Triptorelin

Decapeptyl, Trelstar, Gonapeptyl, Pamorelin

A synthetic GnRH agonist decapeptide that suppresses gonadotropin and sex hormone production for treating prostate cancer, endometriosis, and precocious puberty.

Quick Stats
Studies 178
Trials 100
Formula C64H82N18O13
Clear All
Utility 4
pubmed Dec 5, 2024

Adult height in girls with idiopathic central precocious puberty treated with triptorelin.

Corripio. Raquel R; Soriano-Guillén. Leandro L; Herrero. Francisco-Javier FJ; Castro-Feijo&#xf3...

In girls who start puberty unusually early, giving the hormone blocker triptorelin each month helps them end up closer to the height they’d be expected to reach based on their parents, cutting the loss of adult height that early puberty normally causes.

Utility 4
pubmed Apr 6, 2025

Study of persistence and adherence to ADT in prostate cancer: relugolix, degarelix, and GnRH agonists in the US.

Hafron. Jason J; Hong. Agnes A; Ryan. Michael J MJ; Romdhani. Hela H; Kinkead. Frédéric F;...

A big US study looked at how well men stick with different prostate‑cancer hormone therapies. The only pill‑based option, relugolix, was taken consistently by about 61% of patients after a year, far better than the injectable drugs degarelix and the older GnRH agonists, which saw much lower stick‑rates. People on relugolix also stayed on treatment longer before stopping. This suggests the oral drug is easier to follow in real life, especially for those with advanced cancer.

Utility 4
pubmed Mar 14, 2023

Mitigating the economic burden of GnRH agonist therapy for progestogen-resistant endometriosis: why not?

Vercellini. Paolo P; Bandini. Veronica V; Buggio. Laura L; Barbara. Giussy G; Berlanda. Nicola N; Dr...

Switching the 3.75 mg triptorelin depot injection from every 4 weeks to every 6 weeks still controls pain from endometriosis just as well, but cuts the drug cost by about a third (roughly €744 a year). The review found solid data for this schedule in 4 studies involving 171 women, while other cheaper dosing ideas lacked clear evidence.

Utility 4
pubmed Sep 25, 2021

Dual trigger with the combination of gonadotropin-releasing hormone agonist and standard dose of human chorionic gonadotropin improves <i>in&#xa0;vitro</i> fertilisation outcomes in poor ovarian responders.

Mutlu. Ilknur I; Demirdag. Erhan E; Cevher. Funda F; Erdem. Ahmet A; Erdem. Mehmet M

Adding a small dose of the GnRH‑agonist triptorelin (0.2 mg) to the usual hCG trigger (250 µg) during IVF cycles for women who respond poorly to ovarian stimulation leads to more eggs, more mature eggs, and higher chances of fertilisation, pregnancy and live birth.

Utility 3
pubmed Dec 3, 2025

A retrospective analysis of spontaneous reports of suspected adverse drug reactions to triptorelin acetate in a tertiary pediatric medical center: still a lot of preventable harm.

Cao. Zhongqiang Z; Cheng. Junjie J; Chen. Zebin Z; Lei. Xi X; Yang. Ling L; Zhan. Min M; Chen. Fangz...

The study looked at 38 kids who got triptorelin and had bad reactions, mainly skin problems and serious allergic reactions that happened quickly after the shot. Some severe cases were linked to a change in how the drug was made, showing that even small manufacturing tweaks can cause trouble. The authors suggest testing skin reactions before switching brands to avoid life‑threatening allergies.

Utility 3
pubmed Nov 6, 2024

Efficacy of leuprolide acetate versus triptorelin pamoate administered every 3 months for treatment of central precocious puberty.

Thaneetrakool. Thanaporn T; Aroonparkmongkol. Suphab S; Numsriskulrat. Nattakarn N; Supornsilchai. V...

Both leuprolide acetate and triptorelin pamoate, given every three months, effectively suppress luteinizing hormone in girls with early puberty and lead to similar predicted adult height and bone age outcomes, meaning either drug works equally well for this purpose.

Utility 3
pubmed Oct 15, 2025

Treatment of aggressive prostate cancer with triptorelin in real life in France: the TALISMAN study.

Lebret. Thierry T; Crehange. Gilles G; Pello-Leprince-Ringuet. Nathalie N; Perrot. Val&#xe9;rie V; R...

In France, men with aggressive prostate cancer who start the hormone drug triptorelin usually stick with it for a full year, especially when doctors choose a 3‑month injection based on guidelines and tumor grade. Most patients keep taking the drug continuously, and the safety profile is as expected, with no surprise side effects, though sexual function tends to worsen.

Utility 3
pubmed Nov 11, 2024

Survival, treatment duration and costs of patients with prostate cancer treated with triptorelin in Italy: a study of administrative databases.

Caffo. Orazio O; Facchini. Gaetano G; Esposti. Luca Degli LD; Acciai. Valentina V; Mauri. Giorgio G;...

In a big Italian health database, men with prostate cancer who took the hormone blocker triptorelin lived a long time and stayed on the drug for many years, with the average yearly cost being about €5,600, half of which is the drug itself.

Utility 3
pubmed Feb 7, 2024

Tamoxifen- and Triptorelin-Induced Major Hypertriglyceridemia: A Case Report.

Moussaoui. Widad W; Lahmamssi. Fatima Zahra FZ; Aynaou. Hayat H; Salhi. Houda H; El Ouahabi. Hanan H

A breast cancer patient taking both tamoxifen and the GnRH‑analog triptorelin developed extremely high triglycerides and cholesterol, which dropped after stopping the drugs, changing her diet, and starting fenofibrate. This shows that the combination can sharply worsen blood fats, so anyone using triptorelin (or similar hormones) should keep an eye on their lipid numbers and be ready to adjust diet or medication if needed.

Utility 3
pubmed Dec 23, 2024

Effectiveness, pharmacokinetics, and safety of triptorelin acetate microspheres in patients with locally advanced and metastatic prostate cancer.

Wu. Guolan G; Zhou. Feng F; Wang. Haiping H; Liu. Kan K; Yu. Dexin D; Fan. Lianlian L; Han. Yangyun...

A month‑long injectable form of triptorelin (3.75 mg) reliably lowered testosterone to castration levels in almost all prostate‑cancer patients, staying low for at least three months, and was generally well tolerated, though some people had mild liver enzyme rises, hot flashes, or injection‑site pain.

Utility 3
pubmed Apr 23, 2024

Long-Acting Gonadotropin-Releasing Hormone Analogues for Central Precocious Puberty, Including 45-Mg 6-Month Subcutaneous Leuprolide Acetate: Use for Treatment and Treatment Monitoring.

Silverman. Lawrence A LA; Geffner. Mitchell E ME; Benson. Matthew M

The study shows that a long‑acting GnRH drug called leuprolide acetate, when injected under the skin, works just as well as the traditional intramuscular injection and another drug, triptorelin, at shutting down puberty hormones in kids. The hormone spikes right after the first shot and then stays low with later doses, cutting sex‑steroid levels by more than 98%.

Utility 3
pubmed Aug 14, 2025

Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial.

Demogeot. Nicolas N; Sargos. Paul P; Salleron. Julia J; Gu&#xe9;rif. St&#xe9;phane S; de Crevoisier....

Adding a short, 4‑month course of the hormone blocker triptorelin (with flutamide) before high‑dose radiation improves the chance of staying cancer‑free for men with intermediate‑ or high‑risk prostate cancer, without adding extra serious side effects.

Utility 3
pubmed Sep 1, 2025

Triptorelin associated adverse events evaluated using FAERS pharmacovigilance data.

Jia. Wei W; Wang. Tiezhou T

A big database of FDA side‑effect reports shows that the hormone drug triptorelin, used for prostate cancer and other conditions, is linked to many side effects, including some surprising ones like increased defiant behavior and possible Alzheimer’s‑type dementia. Most problems show up either within the first month or after a year of use, and the timing varies between men and women. These findings don’t prove the drug causes these issues, but they suggest you should be careful and watch for them if you ever consider using triptorelin for health‑hacking purposes.

Utility 3
pubmed Jan 29, 2024

Long-term efficacy of a triptorelin 3-month depot in girls with central precocious puberty.

Park. Kyu Hyun KH; Gwag. Si-Hwa SH; Kim. Yu Jin YJ; Chung. Lindsey Yoojin LY; Kang. Eungu E; Nam. Hy...

A three‑month injection of triptorelin effectively suppresses sex hormones in girls with early puberty, slows bone maturation, and helps them achieve a taller predicted adult height, staying effective throughout the three‑month period.

Utility 3
pubmed Feb 8, 2024

Clinical Outcomes in Hormone Replacement Therapy (HRT)-Frozen Embryo Transfer (FET) Protocol Increased by Administering Gonadotropin-Releasing Hormone Agonist (GnRH) in the Initial Stage of the Luteal Phase: A Retrospective Analysis.

Mahmood. Aamir A; Tan. Li L

Adding the GnRH‑agonist triptorelin to the hormone support given after a frozen embryo transfer (using a hormone‑replacement protocol) raised pregnancy rates from about 48% to 58% and live‑birth rates from about 46% to 53%. The benefit was seen only in the hormone‑replacement cycles, not in natural‑cycle transfers or other protocols. This suggests a short, 3‑4‑dose course of triptorelin in the early luteal phase can improve IVF outcomes, but it’s specific to fertility treatment and not a general health hack.

Utility 3
pubmed Dec 5, 2024

The Role of GnRH Agonist Therapy and Hysterosalpingography (HSG) in Diagnosing and Treating Tubal Factor Infertility.

Katre. Dipti D; Choudhary. Namrata N; Anjankar. Ashish Prakash AP; More. Aakash A; Dakre. Sudhanshu...

A 27‑year‑old woman with severe endometriosis and blocked fallopian tubes was treated with the GnRH‑agonist triptorelin to shrink her endometriosis and control her periods, then underwent IVF using a freeze‑all approach to avoid ovarian hyperstimulation, resulting in a successful pregnancy.

Utility 3
pubmed Jul 4, 2024

A disproportionality analysis of adverse events caused by GnRHas from the FAERS and JADER databases.

Zou. Shupeng S; Ouyang. Mengling M; Zhao. Yazheng Y; Cheng. Qian Q; Shi. Xuan X; Sun. Minghui M

The study looked at big safety databases to see what side‑effects show up when people take GnRH drugs like triptorelin. It found dozens of possible adverse events, some serious (like diabetes or heart failure), and that most problems tend to appear within a few weeks of starting the drug. The findings highlight new safety signals that aren’t listed on the drug label, so users should keep an eye on these risks.